DDrare: Database of Drug Development for Rare Diseases

Searched query = "Generalised pustular psoriasis", "Pustular psoriasis", "Herpetic impetigo", "Generalization of acrodermatitis continua", "Generalization of dermatitis continua of the extremities"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = AIN457; AIN457, 150mg; ANAKINRA; ANB019; Acitretin; Adalimumab; Alefacept; Alvarez 2; Anakinra; Anti-IL-36R monoclonal antibody; BI 655130; BI655130; Brodalumab; Brodalumab 210mg SC; CNTO1959; Calcitriol; Certolizumab Pegol; Certolizumab pegol; Efalizumab; GUSELKUMAB; Guselkumab; Guselkumab 100 mg; Infliximab; Infliximab [infliximab biosimilar 3]; Ixekizumab; KHK4827; KHK4827 140mg SC; KHK4827 210mg SC; LY3074828; MONOCLONAL ANTIBODY ANTI-IGG1; Mirikizumab; Null; P32; P32/98; P32/98 3%; Placebo; Raptiva; Risankizumab; SECUKINUMAB; Secukinumab; Secukinumab 150 mg/1 mL Solution for injection; Secukinumab 150mg; Secukinumab 300mg; Silikis 3µg/g Salbe; Spesolimab; TA-650; TG; TREMFYA®; Tremfya; Ustekinumab

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03942042 (ClinicalTrials.gov)	July 5, 2019	7/5/2019	A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis	A Multicenter, Open-Label, Post Marketing Clinical Trial to Evaluate the Efficacy And Safety Of Ixekizumab in Patients With Generalized Pustular Psoriasis and Erythrodermic Psoriasis	Generalized Pustular Psoriasis;Erythrodermic Psoriasis	Drug: Ixekizumab	Eli Lilly and Company	NULL	Completed	20 Years	N/A	All	12	Phase 4	Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03942042
(ClinicalTrials.gov)

July 5, 2019

7/5/2019

A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis

A Multicenter, Open-Label, Post Marketing Clinical Trial to Evaluate the Efficacy And Safety Of Ixekizumab in Patients With Generalized Pustular Psoriasis and Erythrodermic Psoriasis

Generalized Pustular Psoriasis;Erythrodermic Psoriasis

Drug: Ixekizumab

Eli Lilly and Company

NULL

Completed

20 Years

N/A

All

Phase 4

Japan